Lundbeck gets cold feet, axes schizophrenia drug trial

Lundbeck has axed a phase 2 trial of a schizophrenia drug, saying that the study was unlikely to meet its efficacy target.

The company said it made the decision after a futility analysis indicated that the trial was not likely to succeed, when measured against a standard scale.